IST5-002 | 13484-66-7

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: IST5-002
• 英文别名: N⁶-Benzyladenosin-5'-monophosphat；Benzyl-AMP；N6-Benzyladenosine-5'-phosphate；[(2R,3S,4R,5R)-5-[6-(benzylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
• CAS: 13484-66-7
• 化学式: C₁₇H₂₀N₅O₇P
• 分子量: 437.349
• InChiKey: DWVANBHPEPSMOV-LSCFUAHRSA-N

物化性质

• 沸点：
  798.5±70.0 °C(Predicted)
• 密度：
  1.81±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  172
• 氢给体数：
  5
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  IST5-002 在 palladium on activated charcoal 氢气 作用下， 生成 [[(2R,3S,4R,5R)-5-[6-(benzylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3R,4S)-3,4-dihydroxypyrrolidin-2-yl]methyl hydrogen phosphate
  参考文献：
  名称：

  SAR Analysis of Adenosine Diphosphate (Hydroxymethyl)pyrrolidinediol Inhibition of Poly(ADP-ribose) Glycohydrolase

  摘要：

  Polyadenosine diphosphoribose glycohydrolase (PARG) catalyzes the intracellular hydrolysis of adenosine diphosphoribose polymers. Because structure-activity data are lacking for PARG, the specific inhibitor adenosine diphosphate (hydroxymethyl)pyrrolidinediol (ADP-HPD) was utilized to determine the effects of structure on inhibitor potency using PARG isolated from bovine thymus (bPARG) and recombinant bovine PARG catalytic fragment (rPARG-CF). Both enzymes were strongly inhibited by submicromolar levels of ADP-HPD, but ADP and the phosphorylated pyrrolidine displayed no activity. Utilizing ADP-HPD analogues containing 2-, N-6, or 8-adenosyl substituents or guanine instead of adenine, the importance of adenine ring recognition as well as a correlation between loss of PARG inhibition and the length and bulkiness of 8-adenosyl substituents was shown. Utilization of ADP-HPD analogues lacking one or both pyrrolidine cis-hydroxyls demonstrated their importance for inhibitor binding. Last, the similarity between naturally occurring bPARG and heterologously expressed rPARG-CF was demonstrated. Therefore, readily available rPARG-CF is suitable for use in future studies to determine the structural aspects of PARG.

  DOI：

  10.1021/jm020541u
• 作为产物：
  描述：

  6-苄基腺苷 在 三氯氧磷 作用下， 以 磷酸三甲酯 为溶剂， 生成 IST5-002
  参考文献：
  名称：

  Preparation of (2′-5′)-oligonucleotides based on 6-N-benzylaminopurineriboside using the Spicaria violacea fungal enzyme complex

  摘要：

  提出了一种以 6-N-苄基氨基嘌呤核苷酸为核苷酸单位的（2′-5′）寡核苷酸的化学酶法合成方法。该方法包括酶水解具有混合（2′-5′）-（3′-5′）-磷酸二酯键的寡核苷酸。(3′-5′)特异性核酸内切酶和磷酸酶，通过聚合 6-N- 苄基腺苷-2′(3′)-单磷酸制备而成。

  DOI：

  10.1007/s10600-009-9249-6

文献信息

• TREATMENT OF PROSTATE CANCER AND HEMATOLOGIC NEOPLASMS
  申请人：THOMAS JEFFERSON UNIVERSITY

  公开号：US20150209379A1

  公开（公告）日：2015-07-30

  Prostate cancer and hematological neoplasms are treated by administration of (i) a compound of Formula I: wherein: R 1 is —OH or —O—P(O)(OH) 2 ; and R 2 is (II) or (III); (ii) N 6 -benzyladenosine, (iii) N-(phenylmethyl)-7-β-D-ribofuranosyl-7H-pyrrolo [2,3 -d]pyrimidin-4-amine, (iv) N-(phenylmethyl)-7β-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5′-monophosphate; or a pharmaceutically acceptable salt thereof.

  前列腺癌和血液肿瘤可通过给予以下药物治疗：(i) 公式I中的化合物：其中：R1为—OH或—O—P(O)(OH)2; R2为(II)或(III); (ii) N6-苄基腺嘌呤，(iii) N-(苯甲基)-7-β-D-核糖呋喃基-7H-吡咯[2,3-d]嘧啶-4-胺，(iv) N-(苯甲基)-7β-D-核糖呋喃基-7H-吡咯[2,3-d]嘧啶-4-胺5′-磷酸酯；或其药学上可接受的盐。
• Viral treatment system
  申请人：Prendergast, Patrick T.

  公开号：EP0355825A2

  公开（公告）日：1990-02-28

  This invention relates to pharmaceutical formulations of compounds and drugs for treatment against viruses and prions (proteinaceous infectious particles) eg. CMV, Herpes Simplex, Hepatitis B, Scapie Creutzfeldt-Jakob Disease, in particular for drug treatment of persons and animals suffering from certain retroviral infections, and of persons suffering from infection by retroviruses related to human immuno-deficiency viruses (HIV), and for prophylactic drug treatment of persons who may be suffering from such infections. The anti-viral pharmaceutical formulations according to the invention have the general formula:

  本发明涉及用于治疗病毒和朊病毒（蛋白质感染性颗粒）（如巨细胞病毒、单纯疱疹、乙型肝炎、斯卡皮-克雅氏病）的化合物和药物的药物制剂，特别是用于患有某些逆转录病毒感染的人和动物，以及患有与人类免疫缺陷病毒（HIV）有关的逆转录病毒感染的人的药物治疗，以及可能患有此类感染的人的预防性药物治疗。 根据本发明的抗病毒药物制剂具有通式：
• FMO3 inhibitors for treating pain
  申请人：Akron Molecules GmbH

  公开号：EP2674161A1

  公开（公告）日：2013-12-18

  The present invention relates to new therapies to treat pain and related diseases, as well as pharmaceutical compounds for use in said therapies.

  本发明涉及治疗疼痛和相关疾病的新疗法，以及用于上述疗法的药物化合物。
• Cytidine deaminase expression level in cancer as a new therapeutic target
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US11209421B2

  公开（公告）日：2021-12-28

  The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.

  本发明提供了一种选择肿瘤患者接受抗肿瘤化合物治疗的体外方法，其中该方法包括测量所述患者的癌症样本中CDA（胞苷脱氨酶）的表达水平的步骤。当癌症样本的CDA表达水平低于参考表达水平时，表明患者适合使用选自表4化合物组成的组的抗肿瘤化合物，特别是氨基黄酮进行治疗。或者，当癌症样本的CDA表达水平高于参考表达水平时，表明患者适合使用选自表3化合物组成的组的抗肿瘤化合物，特别是达沙替尼进行治疗。
• Identification of non-lipid LPA3 antagonists by virtual screening
  作者：James I. Fells、Ryoko Tsukahara、Yuko Fujiwara、Jianxiong Liu、Donna H. Perygin、Daniel A. Osborne、Gabor Tigyi、Abby L. Parrill

  DOI：10.1016/j.bmc.2008.04.035

  日期：2008.6

  In the present study, we utilized virtual screening to identify LPA(3) antagonists. We have developed a three-point structure-based pharmacophore model based on known LPA(3) antagonists. This model was used to mine the NCI database. Docking, pharmacophore development, and database mining produced new, non-lipid leads. Experimental testing of seven computationally selected pharmacophore hits produced one potentiator and three antagonists, one of which displays both LPA(3) selectivity and nanomolar potency. Similarity searching in the ChemBridge database using the most promising lead as the search target produced four additional LPA(3) antagonists and a potent dual LPA(1&2) antagonist. (C) 2008 Elsevier Ltd. All rights reserved.